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INTRODUCTION
Dry powder inhaler (DPI) formulations is one of the most useful aerosol preparations in which 
drugs may be formulated as carrier-based interactive mixtures with micronised drug particles 
(<5 µm) adhered onto the surface of large inert carriers (lactose powders). The addition of magnesium 
stearate (MgSt) (1-3), was found to increase dispersion of various drugs from DPI formulations. 
Recently, some active compounds coated with 5% (wt/wt) MgSt using the mechanofusion meth-
od showed significant improvements in aerosolization behavior due to the reduction in intrinsic 
cohesion force (4). Application of MgSt in powder formulations is not new; however, no studies 
demonstrated the minimum threshold level for this excipient in efficient aerosolization of drug 
powders from the interactive mixtures. Therefore, this study investigated the role of MgSt con-
centration on the efficient dispersion of salbutamol sulphate (SS) from DPI formulations. 
METHODS
The powder formulations of SS and lactose carriers (Inhalac 120) were prepared on a laboratory 
scale using a simple hand mixing method (5). Briefly, the required amounts of MgSt (0.1-2.5% 
w/w) were placed between two layers of carrier powder in a glass test tube together with three 
ceramic balls and after sealing, the test tube was vigorously shaken by hand for five minutes. 
Using the same method, 2.5% SS formulations were prepared by mixing SS powders with the 
lactose powders pre-blended with varying concentrations of MgSt. The powder formulations were 
loaded (20 mg) into hard gelatine capsules (size 3, Fawns and McAllan Pty Ltd., Australia). 
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The dispersion of SS from interactive mixtures was determined by Twin Stage Impinger (TSI) with a 
Rotahaler at an airflow rate of 60 L/min. The aerodynamic cut-off diameter at 60L/min was 
6.4µm. The active drug was quantified by a validated HPLC method (6). The particle size dis-
tributions were determined by laser diffraction (Malvern Mastersizer S). The surface morphology 
of the particles was examined using a Quanta 200 Environmental Scanning Electron Microscope 
(FEI Company, The Netherlands). 
RESULTS AND DISCUSSION
The fine particle fraction (FPF) of 2.5 % w/w SS with Inhalac 120 (without MgSt) was 14.8%; 
however, no SS particles were aerosolized without lactose carrier in the formulation. Varying con-
centrations (0.1-2.5%) of MgSt were used as ternary components in the formulations and increased 
concentrations of MgSt over the range 0.1 to 1.5% resulted in a significant increase (ANOVA, 
p<0.05) in FPF (18-33%) of the loaded dose of SS (Figure1) compared to that of formulation with-
out MgSt. However, a trend was observed where the FPF of SS reduced with increasing concentra-
tions of MgSt ≥ 2.0% (Figure 1). In this study, Inhalac 120 lactose crystals were selected because 
of their asymmetric shape (Figure 2A). These particles were nearly free from fine lactose associated 
with large carriers and further removal of the amount of fine lactose was carried out by decantation 
(6) to eliminate the effect of fine lactose in the drug dispersion processes.
The insufficient dispersion of SS from the formulation without MgSt could be due to the 
occupation of the preferential binding sites (cavities/valleys) on the carrier surface by the active or 
strong agglomerates of active. With the introduction of MgSt (0.1-1.5%) in the formulations, the 
FPF of SS was significantly increased due to the reduction in the cohesive behaviour of SS particles 
as well as lowering the adhesion between SS and lactose surface. 
Figure 1. Drug dispersion from the varying concentration of Mg-stearate and 2.5% of SS from the 
interactive mixtures with Inhalac 120.
Respiratory Drug Delivery Europe 2011 – Islam et al. 3
It can be emphasised that 0.1% to 0.2% MgSt would be enough to reduce the cohesive 
forces among SS particles as well as reduce the adhesion between SS and lactose carriers, resulting 
in easy detachment of SS particles from the lactose surface (3). Before the addition of MgSt in 
the formulation, the SS particles were present in large and dense agglomerates (Figure 2, B), from 
where insufficient dispersion occurred. However, loose network structure of SS particles were found 
upon the addition of a minimum amount of MgSt (Figure 2, C and D), which suggested that the 
addition of MgSt produced a significant reduction in cohesive interactions of the SS particles. The 
reduced FPF at higher concentration of MgSt was probably caused due to the transformation of 
the particle force balance from an adhesive back to a cohesive system resulting in re-agglomeration 
of SS particles and phase separation of SS agglomerates as illustrated by Figure 2, E and F. 
Figure 2. SEM micrograph of various compositions: A. Inhalac 120; B. SS; C. Mixture of 0.1% MgSt; 
2.5% SS and Inhalac 120; D. Mixture of 0.5% MgSt, 2.5% SS and Inhalac 120; E. Mixture of 
2.0% MgSt, 2.5% SS and Inhalac 120; F. Mixture of 2.5% MgSt, 2.5% SS and Inhalac 120.
The actual mechanism by which fine excipients like MgSt improves the performance 
of carrier-based DPI formulation is unclear. There is no explanation in the literature how the 
interparticulate interactions are distributed in the components of ternery formulations and the 
relationship between deagglomeration processes and subsequent improvement in drug dispersion. 
Furthermore, no studies demonstrated the theoretical description of the de-agglomeration process 
that occurs during aerosolization of complex ternary formulations. Thus, it is speculated that the 
interactive forces in the ternary formulations are changed in the presence of ternary components 
like MgSt and performance is improved. 
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CONCLUSIONS
The outcome of this study shows that the addition of a minimum amount of MgSt (0.1% w/w) in 
the powder mixtures significantly increased the dispersion of SS. It is hypothesised that this may 
be due to increased de-agglomeration of highly cohesive SS agglomerates via reduction of drug-
carrier adhesion. Thus, this minimum amount of MgSt would be considered to be enough to lower 
the threshold level of the interfacial free energy of interaction between particles, which results in 
efficient de-agglomeration process. The benefit of adding MgSt to the formulation is questionable 
due to the potential risk caused by this excipient being delivered to the deep lung. However, an 
insignificant amount of MgSt from the formulation is expected to be delivered into the deep lungs 
and would not produce negative effects. The proportion of fine excipient like MgSt added in carrier 
based DPI systems has an important role in efficient aerosolization of drug particles. Processing of 
DPI formulation with minimum concentration of this agent is an effective means of improving the 
de-agglomeration and aerosolization of cohesive powders. 
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